Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01714726

Recruitment Status : Completed

First Posted : October 26, 2012

Results First Posted : March 6, 2019

Last Update Posted : March 6, 2019

Sponsor:

Information provided by (Responsible Party):

Allergan

Study Description

Brief Summary:

The study is designed to evaluate the clinical efficacy and safety of MEDI2070 as compared to placebo. Investigational product will be administered as intravenous infusion in double-blind period, and as a subcutaneous injection in open-label period

Condition or disease	Intervention/treatment	Phase
Crohn's Disease	Drug: MEDI2070 Drug: placebo	Phase 2

Detailed Description:

This is a two-part Phase 2a study compromising a 12-week, double-blind, placebo-controlled, treatment period followed by a 100-week, open label, treatment period to evaluate short-term efficacy, and the short- and long-term safety of MEDI2070 in subjects with moderate to severe, active CD who have failed or are intolerant to anti-TNFα therapy as determined by the investigator. Approximately 120 subjects will be randomized in a 1:1 ratio to initially receive a fixed IV dose of MEDI2070 or placebo on Week 0(Day1) and Week 4 (Day 29) during the 12-week, double-blind, placebo-controlled, treatment period. At the completion of the double-blind, placebo-controlled, treatment period (Week 12), subjects will have the option to enter a 100-week, open-label, treatment period where they will receive open-label MEDI2070 (SC) Q4W (Week 12 through Week 112). Subjects will be followed for safety at 3 visits over 28 weeks after their last dose of IP. Subjects will also be contacted by phone 36 weeks after their last dose of IP for safety.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	121 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy
Actual Study Start Date :	February 1, 2013
Actual Primary Completion Date :	May 20, 2014
Actual Study Completion Date :	December 14, 2016

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Crohn disease

MedlinePlus related topics: Crohn's Disease

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: 1 MEDI2070 iv infusion	Drug: MEDI2070 1 iv infusion on Week 0 and Week 4
Placebo Comparator: 2 placebo iv infusion	Drug: placebo 1 iv infusion on Week 0 and Week 4
Experimental: open-label MEDI2070 sc injection; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period	Drug: MEDI2070 1 sc injection of every 4 weeks for 100 weeks, starting at Week 12; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period

Outcome Measures

Primary Outcome Measures :

Percentage of Participants With Crohn's Disease Activity Index (CDAI) Response at Week 8 [ Time Frame: Week 8 ]
A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes subject reported symptoms, physician-assessed signs, and laboratory markers. CDAI score = Sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (associated signs, use of anti-diarrhoeal medication, abdominal mass, haematocrit, daily morning temperature, body weight). CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity. The CDAI response at Week 8 is defined as either CDAI score of less than (<)150 or CDAI reduction from baseline of at least 100 points, where baseline was last non-missing observation prior to first administration of the study drug. Modified Intent-to-treat (mITT)population was analysed for this end point, which included all subjects who were randomized and received at least 1 dose of study drug in double-blind period.

Secondary Outcome Measures :

Percentage of Participants With CDAI Remission at Week 8 [ Time Frame: Week 8 ]
The CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days and includes subject reported symptoms, physician-assessed signs, and laboratory markers. The CDAI score is calculated by summing weighted scores for subjective items (number of liquid or very soft stools, the degree of abdominal pain over a week and general well-being; and objective items (associated signs, use of anti-diarrhoeal medication, abdominal mass, haematocrit, daily morning temperature, and body weight). The CDAI scores range approximately from 0 to 600, with higher scores indicating greater disease activity. The CDAI score of < 150 represent CDAI remission. Subjects in the mITT population were analysed for this end point.
Percentage of Participants With CDAI-100 Point Improvement at Week 8 [ Time Frame: Week 8 ]
The CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days and includes subject reported symptoms, physician-assessed signs, and laboratory markers. The CDAI score is calculated by summing weighted scores for subjective items (number of liquid or very soft stools, the degree of abdominal pain over a week and general well-being; and objective items (associated signs, use of anti-diarrhoeal medication, abdominal mass, haematocrit, daily morning temperature, and body weight). The CDAI scores range approximately from 0 to 600, with higher scores indicating greater disease activity. CDAI 100-point improvement is defined as a reduction from baseline in CDAI score of at least 100 points/scores, where baseline was the latest nonmissing observation prior to first administration of the study drug. Subjects in the mITT population were analysed for this end point.
Percentage of Participants With CDAI-70 Point Improvement at Week 8 [ Time Frame: Week 8 ]
The CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days and includes subject reported symptoms, physician-assessed signs, and laboratory markers. The CDAI score is calculated by summing weighted scores for subjective items (number of liquid or very soft stools, the degree of abdominal pain over a week and general well-being; and objective items (associated signs, use of anti-diarrhoeal medication, abdominal mass, haematocrit, daily morning temperature, and body weight). The CDAI scores range approximately from 0 to 600, with higher scores indicating greater disease activity. CDAI 70-point improvement is defined as a reduction from baseline in CDAI score of at least 70 points/scores, where baseline was the latest nonmissing observation prior to first administration of the study drug. Subjects in the mITT population were analysed for this end point.
Percentage of Participants With CDAI Response at Week 12 [ Time Frame: Week 12 ]
The CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days and includes subject reported symptoms, physician-assessed signs, and laboratory markers. The CDAI score is calculated by summing weighted scores for subjective items (number of liquid or very soft stools, the degree of abdominal pain over a week and general well-being; and objective items (associated signs, use of anti-diarrhoeal medication, abdominal mass, haematocrit, daily morning temperature, and body weight). The CDAI scores range approximately from 0 to 600, with higher scores indicating greater disease activity. CDAI response is defined by either a CDAI score of < 150 or a CDAI reduction from baseline of at least 100 points, where baseline was the latest non-missing observation prior to first administration of the study drug. Subjects in the mITT population were analysed for this end point.
Change From Baseline in CDAI Total Score at Week 8 [ Time Frame: Week 8 ]
The CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days and includes subject reported symptoms, physician-assessed signs, and laboratory markers. The CDAI score is calculated by summing weighted scores for subjective items (number of liquid or very soft stools, the degree of abdominal pain over a week and general well-being; and objective items (associated signs, use of anti-diarrhoeal medication, abdominal mass, haematocrit, daily morning temperature, and body weight). The CDAI scores range approximately from 0 to 600, with higher scores indicating greater disease activity. Subjects in the mITT population were analysed for this end point.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Double-blind Period [ Time Frame: From study drug administration (Day 1) to 36 weeks post last blinded dose (up to 48 weeks) ]
An Adverse Event (AE) is any unfavourable and unintended sign, symptoms, or diseases temporally associated with use of study drug, whether or not considered related to study drug. A serious adverse event (SAE) is any AE that resulted in death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, lifethreatening, a congenital anomaly/birth defect, or an important medical event. The TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug (Day 1) to 36 weeks post treatment (approximately 48 weeks). The safety population was analysed for this end point, which included all subjects who received any amount of study drug.
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs) in Double-blind Period [ Time Frame: From study drug administration (Day 1) to 36 weeks post last blinded dose (up to 48 weeks) ]
An Adverse Event (AE) is any unfavourable and unintended sign, symptoms, or diseases temporally associated with use of study drug, whether or not considered related to study drug. A serious adverse event (SAE) is any AE that resulted in death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, lifethreatening, a congenital anomaly/birth defect, or an important medical event. The TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug (Day 1) to 36 weeks post treatment (approximately 48 weeks). The safety population was analysed for this end point, which included all subjects who received any amount of study drug.
Number of Participants With TEAEs in Open-label Period [ Time Frame: From first open-label dose administration (Week 12) to 36 weeks post last dose (up to 148 weeks) ]
An AE is any unfavourable and unintended sign, symptoms, or diseases temporally associated with use of study drug, whether or not considered related to study drug. A SAE is any AE that resulted in death,inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, lifethreatening, a congenital anomaly/birth defect, or an important medical event. The TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug (Day 1) to 36 weeks post treatment (approximately 148 weeks). Open-label population was analysed for this endpoint, which included all subjects who were enrolled in the 100-week, open-label treatment period and have at least one dose of open-label MEDI2070 210 mg SC treatment.
Number of Participants With TESAEs in Open-label Period [ Time Frame: From first open-label dose administration (Week 12) to 36 weeks post last dose (up to 148 weeks) ]
An AE is any unfavourable and unintended sign, symptoms, or diseases temporally associated with use of study drug, whether or not considered related to study drug. A SAE is any AE that resulted in death,inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, lifethreatening, a congenital anomaly/birth defect, or an important medical event. The TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug (Day 1) to 36 weeks post treatment (approximately 148 weeks). Open-label population was analysed for this endpoint, which included all subjects who were enrolled in the 100-week, open-label treatment period and have at least one dose of open-label MEDI2070 210 mg SC treatment.
Number of Participants With Clinical Laboratory Abnormalities as TEAEs in Double-blind Period [ Time Frame: From study drug administration (Day 1) to 36 weeks post last blinded dose (up to 48 weeks) ]
The TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug (Day 1) to 36 weeks post treatment (up to approximately 48 weeks). Subjects in the safety population were analysed for this end point.
Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Open-label Period [ Time Frame: From first open-label dose administration (Week 12) to 36 weeks post last dose (up to 148 weeks) ]
The TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug (Day 1)to 36 weeks post treatment (up toapproximately 148 weeks). Open-label population was analysed for this endpoint, which included all subjects who were enrolled in the 100-week, open-label treatment period and have at least one dose of open-label MEDI2070 210 mg SC treatment.
Number of Participants With Vital Signs Abnormalities Reported as TEAEs in Double-blind Period [ Time Frame: From study drug administration (Day 1) to 36 weeks post last blinded dose (up to 48 weeks) ]
The TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug (Day 1)to 36 weeks post treatment(approximately 48 weeks). Subjects in the safety population were analysed for this end point.
Number of Participants With Vital Signs Abnormalities Reported as TEAEs in Open-label Period [ Time Frame: From first open-label dose administration (Week 12) to 36 weeks post last dose (up to 148 weeks) ]
The TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug (Day 1) to 36 weeks post treatment(approximately 148 weeks). Open-label population was analysed for this endpoint, which included all subjects who were enrolled in the 100-week, open-label treatment period and have at least one dose of open-label MEDI2070 210 mg SC treatment.
Maximum Mean Serum Concentration of MEDI2070 in Doubleblind Period [ Time Frame: Post-dose on Week 0 (Day 1); pre and post-dose on Week 4; pre-dose on Week 8 ]
Pharmacokinetic (PK) population included all subjects who received at least one dose of MEDI2070(either in double-blind period or in open-label period) and had at least one PK sample that was above the lower limit of quantification was considered for this end point. Serum concentration of MEDI2070 for subject in 'Placebo' arm is not applicable for this time frames and is reported by an arbitrary value (NA).
Maximum Mean Serum Concentration of MEDI2070 in Open-label Period [ Time Frame: Pre-dose on Weeks 12, 24, and 112 ]
The PK population included all subjects who received at least one dose of MEDI2070 (either in double-blind period or in open-label period) and had at least one PK sample that was above the lower limit of quantification was considered for this end point. Serum concentration of MEDI2070 for subject in 'Placebo' arm is not applicable for pre-dose Week 12 time frame and is reported by an arbitrary value (NA).
Number of Participants With Positive Anti-drug Antibody (ADA) to MEDI2070 in Double-blind Period [ Time Frame: Baseline (Week0/Day 1) up to 28 week post last dose (approximately 40 weeks) ]
The PK population included all subjects who received at least one dose of MEDI2070 (either in double-blind period or in open-label period) and had at least one PK sample that was above the lower limit of quantification was considered for this end point.
Number of Participants With ADA Positive to MEDI2070 in Open-label Period [ Time Frame: Up to 28 week post last dose (approximately 140 weeks) ]
The PK population included all subjects who received at least one dose of MEDI2070 (either in double-blind period or in open-label period) and had at least one PK sample that was above the lower limit of quantification was considered for this end point.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Diagnosed ileal, ileo-colonic, or colonic CD at least 6 months prior to screening.
Men or women age 18 - 65 years at the time of screening.
Moderate-sever active Crohn's Disease (CD), defined by a Crohn's Disease Activity Index (CDAI) score higher or equal 220 and lower or equal 450 at Day 1.
No known history of active tuberculosis (TB).
Received at least one anti-TNFα agent for the treatment of CD and did not initially respond.

Exclusion Criteria:

Pregnant or breastfeeding women.
Presence of ileostomy and/or colostomy.
Short bowel syndrome.
Bowel perforation or obstruction.
History of cancer.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01714726

Locations

Show 48 study locations

Layout table for location information

United States, California
Precision Research Institute, LLC
Chula Vista, California, United States, 91910
United States, Colorado
Rocky Mountain Clinical Research
Lakewood, Colorado, United States, 80215
United States, Florida
Borland Groover Clinic
Jacksonville, Florida, United States, 32256
University of Miami
Miami, Florida, United States, 33136
Shafran Gastroenterology Center
Winter Park, Florida, United States, 32789
United States, Georgia
Gastroenterology Associates of Central Georgia
Macon, Georgia, United States, 31201
United States, Illinois
University Chicago Medical Center
Chicago, Illinois, United States, 60637
United States, Maryland
Metropolitan Gastroenterology Group
Chevy Chase, Maryland, United States, 20815
United States, Michigan
University of Michigan Health Care System
Ann Arbor, Michigan, United States, 48109
Troy Internal Medicine PC
Troy, Michigan, United States, 48098
United States, Missouri
Ehrhardt Clinical Research, LLC
Belton, Missouri, United States, 64012
United States, New York
Weill Medical College
New York, New York, United States, 10021
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
United States, North Carolina
Charlotte Gastroenterology & Hepatology
Charlotte, North Carolina, United States, 28207
United States, Ohio
Consultants for Clinical Research Inc.
Cincinnati, Ohio, United States, 32789
Canada, Alberta
Zeidler Ledcor Centre
Edmonton, Alberta, Canada, T6G 2X8
Canada, British Columbia
GI Research Institute
Vancouver, British Columbia, Canada, V6Z 2K5
Canada, Ontario
Hotel Dieu Hospital
Kingston, Ontario, Canada, K7L 5G2
London Health Sciences Centre
London, Ontario, Canada, N6A 5A5
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5
Toronto Digestive Disease Associates
Vaughan, Ontario, Canada, L2L 4Y7
Czechia
Hepato-Gastroenterologie HK
Hradec Kralove, Czechia
Fakultni nemocnice Ostrava -
Ostrava-Poruba, Czechia
Fakultni nemocnice Kralovske Vinohrady
Praha 10, Czechia
France
CHU Amiens Picardie Service Hépato-gastroentérologie
Amiens Cedex 1, France
Hôpital Beaujon Service de Gastroentérologie et Assistance Nutritive
Clichy, France
Hôpital Charles Nicolle Service d'Hepato-Gastroentérologie1, Rue De Germont Pavillon Derocque
Rouen, France
Hôpital de Rangueil1 avenue du Professeur Jean Poulhès Service de Gastroentérologie et de Nutrition
Toulouse Cedex 9, France
Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Praxis Dr. med. Constanze & Dr. med. Wolfgang Brandt Facharzt für Innere MedizinRudolf-Breitscheid-Str.
Potsdam, Germany
Hungary
Peterfy S. utcai Korhaz-Rend.Int es Baleseti Kozp.
Budapest, Hungary
Szent János Kórház és Észak-budai Egyesített Kórházak
Budapest, Hungary
Vas Megyei Markusovszky Kórház Nonprofit Zrt.
Budapest, Hungary
Italy
Azienda Ospedaliera Policlinico S. Orsola - Malpighi
Bologna, Italy
Azienda Ospedaliera Universitaria Careggi
Firenze, Italy
Ii Università Degli Studi Di Napoli
Napoli, Italy
A.O. Policlinico Universitario "Tor Vergata"
Roma, Italy
Università Cattolica del Sacro Cuore-Policlinico A. Gemelli Complesso Integrato Columbus
Roma, Italy
Istituto Clinico "Humanitas"
Rozzano, Italy
Poland
Szpital Uniwersytecki nr 2 im. Jana Biziela w Bydgoszczy Centrum Endoskopii Zabiegowej
Bydgoszcz, Poland
Endoskopia Sp. z o. o. ul.
Sopot, Poland
Centralny Szpital Kliniczny MSW w Warszawie
Warszawa, Poland
Spain
CEIC Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
CEIC Hospital Universitàrio de Bellvitge
Barcelona, Spain
Hospital de la Santa Creu i Saint Pau Avda. Sant Antoni Mª Claret
Barcelona, Spain
Sabadell, H. Parc Taulí,Ap.Digestivo Aparatro DigestivoParc Taulí
Barcelona, Spain
Hospital Universitario Virgen Macarena
Sevilla, Spain

Sponsors and Collaborators

Allergan

Investigators

Layout table for investigator information

Study Director:	Carl Gommoll, MS	Allergan

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sands BE, Chen J, Feagan BG, Penney M, Rees WA, Danese S, Higgins PDR, Newbold P, Faggioni R, Patra K, Li J, Klekotka P, Morehouse C, Pulkstenis E, Drappa J, van der Merwe R, Gasser RA Jr. Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study. Gastroenterology. 2017 Jul;153(1):77-86.e6. doi: 10.1053/j.gastro.2017.03.049. Epub 2017 Apr 5.

Layout table for additonal information

Responsible Party:	Allergan
ClinicalTrials.gov Identifier:	NCT01714726
Other Study ID Numbers:	D5170C00001 2012-004098-26 ( EudraCT Number )
First Posted:	October 26, 2012 Key Record Dates
Results First Posted:	March 6, 2019
Last Update Posted:	March 6, 2019
Last Verified:	March 2019

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Allergan:


MEDI2070 inflammatory bowel disease moderate to severe Crohn's disease

Additional relevant MeSH terms:

Layout table for MeSH terms

Crohn Disease Inflammatory Bowel Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases	Intestinal Diseases Antibodies, Monoclonal Immunologic Factors Physiological Effects of Drugs

To Top